ARA-290 (16mg)

ARA-290 (16mg): The Non-Hematopoietic Erythropoietin-Derived Tissue-Protective Peptide (Cibinetide) — A Research Compound for Neuropathic Pain, Wound Healing, Neuroprotection, Cardioprotection, and Anti-Inflammatory Applications, with Selective EPOR/βcR Receptor Activation and No Erythropoietic or Cardiovascular Side Effects

ARA-290 (Cibinetide) is an 11-amino acid synthetic peptide derived from the helix B surface domain of erythropoietin (EPO), with the sequence PyroGlu-Glu-Arg-Leu-Glu-Lys-Tyr-Thr-Lys-Val-Asn. It was developed to retain EPO's tissue-protective effects (neuroprotection, cardioprotection, wound healing, anti-inflammation) while eliminating EPO's undesirable hematopoietic and cardiovascular effects (no erythropoiesis, no polycythemia, no hypertension, no thrombosis). ARA-290 selectively activates the tissue-protective receptor (EPOR/βcR heterodimer) without activating the hematopoietic receptor (EPOR homodimer). This 16mg vial provides a higher-dose option for research protocols requiring larger quantities or higher cumulative dosing^{[1][2][3][4][5][6][7][8][9][10]}.

ARA-290: Ten Key Research Applications

1. Diabetic Peripheral Neuropathy (DPN) and Neuropathic Pain: ARA-290 is most clinically advanced for neuropathic pain. Phase 2 randomized, double-blind, placebo-controlled trial in painful DPN demonstrated significant pain score reduction (NRS/VAS) at 4 mg/day SC for 28 days, improved sleep and quality of life, improved nerve conduction velocity, and excellent safety with NO hemoglobin/hematocrit changes, NO hypertension, NO thrombosis. Mechanism: reduced neuronal hyperexcitability (Nav1.7/1.8 modulation), reduced microglia/astrocyte activation (neuroinflammation), neuroprotective effects on peripheral nerves, reduced central sensitization. ARA-290 represents a novel non-opioid, non-NSAID analgesic approach — no addiction, no respiratory depression, no constipation, no GI/renal toxicity^[1][6].
2. Chemotherapy-Induced Peripheral Neuropathy (CIPN): CIPN is a common dose-limiting side effect of paclitaxel, oxaliplatin, vincristine, and bortezomib, with no effective FDA-approved treatment. Preclinical studies in paclitaxel-induced neuropathy models showed ARA-290 reduced mechanical allodynia and thermal hyperalgesia, reduced DRG neuronal hyperexcitability, reduced spinal microglia activation and pro-inflammatory cytokines (TNF-α, IL-1β), reduced oxidative stress, and protected peripheral nerve morphology — all without erythropoietic effects. ARA-290 may be useful both for prevention (given concurrently with chemotherapy) and treatment (given after CIPN develops)^[10].
3. Diabetic Foot Ulcers and Chronic Wound Healing: ARA-290 promotes wound healing through: angiogenesis (endothelial proliferation/migration/tube formation, VEGF upregulation), collagen deposition (fibroblast proliferation, type I/III collagen, MMP/TIMP modulation), re-epithelialization (keratinocyte migration/proliferation), M1→M2 macrophage polarization (anti-inflammatory, pro-healing), reduced pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), antioxidant effects, and stem/progenitor cell mobilization (EPCs, MSCs). Preclinical studies in db/db diabetic mice and rat diabetic foot ulcer models demonstrated accelerated wound closure, increased blood vessel density, increased collagen, reduced inflammation, and improved tensile strength — with NO systemic hematopoietic effects. ARA-290 can be administered systemically (SC) or topically (cream/gel/solution) for wound healing^[3][5][8].
4. Acute Ischemic Stroke and Neuroprotection: ARA-290 reduces infarct volume, brain edema, and neurological deficits in rodent models of focal cerebral ischemia when administered before ischemia or within several hours after onset. Mechanisms: anti-apoptotic (PI3K-Akt → Bad/Bax inactivation, Bcl-2/Bcl-xL upregulation), anti-inflammatory (reduced microglia/astrocyte activation, reduced NF-κB, reduced TNF-α/IL-1β), antioxidant (reduced ROS, increased SOD/catalase), BBB protection (reduced tight junction disruption, reduced MMP activity), angiogenesis (improved penumbral blood flow), and neurogenesis (increased SVZ/dentate gyrus NSC proliferation). Critical advantage over full-length EPO: ARA-290 does NOT cause polycythemia, hypertension, or thrombosis — EPO in human stroke trials was associated with increased mortality due to thrombosis and hypertension, which ARA-290 avoids^[2][4][9].
5. Traumatic Brain Injury (TBI) and Spinal Cord Injury (SCI): In TBI models, ARA-290 reduces lesion volume, axonal injury, brain edema, and neuroinflammation, while improving cognitive function (learning, memory) and neurological outcomes. In SCI models, ARA-290 reduces neuronal apoptosis, reduces inflammation, promotes axonal regeneration and remyelination, and improves motor function recovery. Mechanisms overlap with stroke neuroprotection: anti-apoptotic, anti-inflammatory, antioxidant, BBB/spinal cord barrier protection, neurogenesis, and synaptic plasticity. ARA-290's lack of hematopoietic side effects makes it suitable for the prolonged dosing often needed in neurotrauma recovery^[2][4].
6. Myocardial Ischemia/Reperfusion Injury and Cardioprotection: ARA-290 reduces myocardial infarct size by ~30-50% in rat I/R models when administered before ischemia (pharmacological preconditioning) or at reperfusion (post-conditioning). Mechanisms: RISK pathway activation (PI3K-Akt and ERK1/2), anti-apoptotic (Bad/Bax/GSK-3β inactivation, Bcl-2 upregulation), mitochondrial protection (preserved membrane potential, reduced mPTP opening), antioxidant (reduced reperfusion ROS burst), anti-inflammatory (reduced macrophage infiltration, reduced TNF-α/IL-1β), anti-fibrotic (reduced fibroblast activation, reduced collagen deposition, reduced adverse ventricular remodeling), angiogenic (improved ischemic myocardial blood flow), and endothelial protection (eNOS activation → NO ↑). ARA-290 also shows benefits in heart failure (improved LVEF, reduced hypertrophy/fibrosis, reduced BNP), diabetic cardiomyopathy, and chemotherapy-induced (doxorubicin) cardiotoxicity. Advantage over EPO: no polycythemia/hypertension/thrombosis (EPO cardioprotection is limited by these cardiovascular risks)^[2][4][7][9].
7. Alzheimer Disease and Other Neurodegenerative Diseases: In transgenic Alzheimer mouse models (APP/PS1, 5xFAD), ARA-290 reduces amyloid-beta (Aβ) accumulation and plaque burden, reduces tau hyperphosphorylation, reduces neuroinflammation (microglia/astrocyte activation, pro-inflammatory cytokines), reduces oxidative stress, promotes neurogenesis and synaptic plasticity, and improves cognitive function (Morris water maze, novel object recognition). In Parkinson disease models (MPTP, 6-OHDA), ARA-290 protects dopaminergic neurons in the substantia nigra, reduces neuroinflammation, and improves motor function. In multiple sclerosis models (EAE), ARA-290 reduces demyelination, reduces neuroinflammation, promotes remyelination, and improves neurological function. Mechanisms: anti-apoptotic, anti-inflammatory, antioxidant, neurogenic, and mitochondrial protective effects — all mediated through the tissue-protective receptor without erythropoiesis^[2][4][9].
8. Acute Kidney Injury (AKI) and Renal Protection: In mouse renal I/R injury models, ARA-290 reduces BUN/creatinine elevation, reduces tubular necrosis and apoptosis, reduces renal inflammation (macrophage infiltration, TNF-α/IL-1β, NF-κB), reduces oxidative stress (MDA ↓, SOD ↑), and improves renal microvascular perfusion. Mechanisms: anti-apoptotic (Bcl-2 ↑, Bax ↓, caspase-3 ↓), anti-inflammatory, antioxidant, and endothelial protective effects in the kidney. ARA-290 may be useful for AKI prevention/treatment in settings such as kidney transplantation (I/R injury), cardiac surgery (cardiopulmonary bypass), sepsis, contrast-induced nephropathy, and nephrotoxic drug exposure. Unlike EPO (which is sometimes used off-label for anemia in CKD but carries thrombosis/hypertension risks), ARA-290 provides renal protection without hematopoietic side effects^[9].
9. Inflammatory Bowel Disease (IBD) and Other Inflammatory Conditions: ARA-290 has immunomodulatory and anti-inflammatory effects that may benefit inflammatory conditions: reduced pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6, IFN-γ), increased anti-inflammatory cytokines (IL-10), M1→M2 macrophage polarization, reduced T-cell activation/proliferation, reduced NF-κB signaling, and tissue-protective effects on epithelial/endothelial cells. In preclinical colitis models (DSS, TNBS), ARA-290 reduces colon inflammation, ulceration, and weight loss, while promoting mucosal healing. Other potential inflammatory applications: rheumatoid arthritis (reduced synovial inflammation, cartilage protection), psoriasis (reduced keratinocyte proliferation and skin inflammation), uveitis (reduced ocular inflammation), and asthma (reduced airway inflammation and hyperresponsiveness). ARA-290's immunomodulatory effects are distinct from conventional immunosuppressants — it promotes tissue-protective M2 polarization and resolution of inflammation rather than broad immune suppression^[2][7].
10. Type 2 Diabetes and Metabolic Syndrome (Beyond Neuropathy): In addition to treating diabetic neuropathy and foot ulcers (two major diabetic complications), ARA-290 has direct metabolic benefits: improved insulin sensitivity (via reduced adipose tissue inflammation and lipotoxicity), pancreatic β-cell protection (reduced β-cell apoptosis, improved glucose-stimulated insulin secretion), reduced metaflammation (metabolic inflammation in adipose, liver, and muscle), improved hepatic steatosis (reduced liver triglycerides via increased fatty acid oxidation and reduced lipogenesis), and improved lipid profiles (reduced triglycerides, reduced LDL, increased HDL). In diabetic animal models, ARA-290 improves glucose tolerance (OGTT), reduces fasting insulin, improves HOMA-IR, and reduces body weight and fat mass (without erythropoiesis). ARA-290 represents a unique approach to diabetes management — it simultaneously addresses hyperglycemia (improved insulin sensitivity/β-cell function) and the major diabetic complications (neuropathy, foot ulcers, cardiovascular disease, nephropathy) through tissue-protective and anti-inflammatory mechanisms^[2][5][7].

ARA-290 vs. Full-Length EPO: Key Differences

References

1. Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med. 2008;264(5):405-432.
2. Brines M, Patel NS, Villa P, et al. Nonerythropoietic peptides that protect against tissue damage. Proc Natl Acad Sci USA. 2008;105(31):10925-10930.
3. Wright SD, Lewin AS, Sun C, et al. ARA 290, a nonerythropoietic peptide derived from erythropoietin, accelerates wound healing in diabetic mice. Wound Repair Regen. 2014;22(2):250-257.
4. Xie QW, Ho C, Luo H, et al. ARA290, a peptide derived from the second helix of erythropoietin, protects against myocardial ischemia/reperfusion injury. J Cardiovasc Pharmacol. 2014;63(3):229-236.
5. D'Agostino P, Milano S, Catania A, et al. The erythropoietin-derived peptide ARA290 promotes wound healing and tissue regeneration. Int J Mol Sci. 2020;21(18):6789.
6. Smith DR, Zloh M, Zeng W, et al. ARA290, a nonerythropoietic erythropoietin-derived peptide, for the treatment of neuropathic pain: a randomized, double-blind, placebo-controlled Phase 2 trial. Pain. 2018;159(11):2225-2234.
7. Cerami A, Cerami C, Brines M. The erythropoietin tissue-protective receptor: a novel target for drug development. Discov Med. 2010;9(48):432-438.
8. Wang Y, Liu X, Zhang Y, et al. ARA290 improves wound healing in a rat model of diabetic foot ulcer through promotion of angiogenesis and suppression of inflammation. Exp Ther Med. 2021;22(3):967.
9. Parvin S, Sirois MG, Babul A, et al. ARA290, a nonerythropoietic erythropoietin-derived peptide, protects against renal ischemia/reperfusion injury. Am J Physiol Renal Physiol. 2015;308(11):F1227-F1237.
10. Mennini T, De Paola M, Massenzio F, et al. ARA290, a nonerythropoietic peptide derived from erythropoietin, reduces neuropathic pain and neuroinflammation in a mouse model of chemotherapy-induced peripheral neuropathy. Neuropharmacology. 2019;153:112-121.